AR027686A1 - USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD - Google Patents

USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD

Info

Publication number
AR027686A1
AR027686A1 ARP010101290A ARP010101290A AR027686A1 AR 027686 A1 AR027686 A1 AR 027686A1 AR P010101290 A ARP010101290 A AR P010101290A AR P010101290 A ARP010101290 A AR P010101290A AR 027686 A1 AR027686 A1 AR 027686A1
Authority
AR
Argentina
Prior art keywords
treatment
coagulation
extracorpore
blood
inhibiting substances
Prior art date
Application number
ARP010101290A
Other languages
Spanish (es)
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of AR027686A1 publication Critical patent/AR027686A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere al uso de sustancias activas inhibidoras de la coagulacion, y especialmente de PEG-hirudina, para el tratamiento de individuos concirculacion extracorporea para la profilaxis de complicaciones vasculares después de la circulaci on extracorporea. Así se pueden tratar sobre todo losindividuos con insuficiencia renal cronica con requerimiento regular de hemodiálisis y de este modo pueden ser protegidos contra complicaciones vasculares, quecomunmente tienen una alta tasa de mor bilidad y mortalidad en los pacientes tratados en forma constante con diálisis.This refers to the use of active substances that inhibit coagulation, and especially PEG-hirudin, for the treatment of individuals with extracorporeal circulation for the prophylaxis of vascular complications after extracorporeal circulation. In this way, individuals with chronic renal insufficiency with regular hemodialysis requirements can be treated and can thus be protected against vascular complications, which usually have a high morbidity and mortality rate in patients treated constantly with dialysis.

ARP010101290A 2000-03-20 2001-03-20 USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD AR027686A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19010300P 2000-03-20 2000-03-20
EP00105867 2000-03-20

Publications (1)

Publication Number Publication Date
AR027686A1 true AR027686A1 (en) 2003-04-09

Family

ID=26070693

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101290A AR027686A1 (en) 2000-03-20 2001-03-20 USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD

Country Status (6)

Country Link
EP (1) EP1265639A1 (en)
JP (2) JP5367202B2 (en)
AR (1) AR027686A1 (en)
AU (1) AU2001248355A1 (en)
CA (1) CA2404115A1 (en)
WO (1) WO2001070273A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105102612B (en) * 2012-12-06 2020-11-17 恩立夫克治疗有限责任公司 Therapeutic apoptotic cell preparations, methods of making and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341414C (en) * 1984-03-27 2002-12-31 Paul Tolstoshev Expression vectors of hirudine, transformed cells and process for the preparation of hirudine
HUT57060A (en) * 1988-12-05 1991-11-28 Biogen Inc Process for producing compositions for inhibiting blood platelet aggregation
CA2067224C (en) * 1989-12-01 2001-02-13 Manfred Kurfuerst Hirudin/polyalkylene glycol conjugates
JPH05168705A (en) * 1991-06-11 1993-07-02 Toray Ind Inc System removing von willebrand factor
JPH05220218A (en) * 1992-02-13 1993-08-31 Norio Nakabayashi Anti-thrombogenic regeneration cellulose film and manufacture thereof
DE4242655A1 (en) * 1992-12-17 1994-06-23 Behringwerke Ag Use of thrombin inhibitors to inhibit ocular fibrin formation
DE19715504C2 (en) * 1997-04-14 2000-10-26 Max Planck Gesellschaft PMMA membranes with polyethylene glycol-coupled active substances
JP3601662B2 (en) * 1998-07-24 2004-12-15 東洋紡績株式会社 Blood purification membrane with improved antithrombotic properties

Also Published As

Publication number Publication date
WO2001070273A1 (en) 2001-09-27
EP1265639A1 (en) 2002-12-18
CA2404115A1 (en) 2001-09-27
JP2003527442A (en) 2003-09-16
JP2012006964A (en) 2012-01-12
AU2001248355A1 (en) 2001-10-03
JP5367202B2 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
MX2022010313A (en) Blood treatment systems and methods.
WO2001007067A3 (en) Solutions and methods for inhibition of pain, inflammation and cartilage degradation
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2009022417A1 (en) Peritoneal dialysate
PT1220670E (en) USES OF L-CARNITINE AND ITS ALCANOYL DERIVATIVES AS OSMOTIC AGENTS IN SOLUTIONS FOR MEDICAL USE.
SE9900043D0 (en) New use
Andreucci et al. Edema and acute renal failure
ITMI20020526A1 (en) VENOUS BLOOD TANK IN EXTRACORPOREAL CIRCUIT
AR027686A1 (en) USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD
EA200600695A1 (en) PROTECTING TISSUE CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPSIS AND FORMATION
ES2198359T3 (en) USE OF URODILATINE FOR THE TREATMENT OF CHRONIC RENAL FAILURE WITH RESIDUAL RENAL FUNCTIONS.
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
AR033089A1 (en) ABSORBENT PRODUCT
Rogers Indications for cadaver skin in burns and complex wound care: SA Burn Society Congress
WO2002015893A3 (en) Treatment of wounds
SE0301546D0 (en) Biocompatible polymer
Krediet Osmotic agents in automated peritoneal dialysis solutions
Scribner Dialysis dose: higher is better.
DE602004028234D1 (en) BIOKOMPATIBLE POLYMER
Wai-Leung et al. Effects of peritoneal dialysate acidity on the net ultrafiltration and solute removal in patients on intermittent peritoneal dialysis
Palmer Preventing Intradialytic Hypotension.
Shetty et al. Ultrafiltration failure in CAPD
Nicolaides et al. Surgical thrombectomy
Adachi et al. Tidal automated peritoneal dialysis preserves residual renal function better than non tidal automated peritoneal dialysis
Roessler et al. Pulse High-Volume Hemofiltration in Management of Critically Ill Patients with Severe Sepsis or Septic Shock